Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal
implant manufacturer, today announced its financial results for the
second quarter ended June 30, 2014.
- Worldwide sales were $113.6 million, a
6.1% increase over the second quarter 2013
- Second quarter net income was $20.6
million, compared to $7.4 million last year
- Earnings per diluted share (EPS) were
$0.22 in the quarter, compared to $0.08 in 2013
- Non-GAAP EPS was $0.23, up from $0.21
in the second quarter of 2013
- Quarterly Non-GAAP Adjusted EBITDA was
35.4%, an increase over the 34.0% in 2013
David Paul, Chairman and CEO said, "Quarterly sales were up 6.1%
over last year, and we continue to execute and produce strong
profitability while maintaining our steadfast focus on product
innovation. This quarter we launched five new products including
CREO® Threaded, part of our growing new pedicle screw platform,
CREO®. CREO® Threaded offers controlled gradual correction for
complex deformity users who prefer threaded locking caps and
addresses the largest segment of the spine market. We are confident
in our long term growth prospects and our ability to sustain our
industry leading profitability by continued execution of our
business model."
Second quarter net sales were $113.6 million, as compared to
$107.0 million last year, representing a 6.1% increase. Sales in
the US and international grew by 3.6% and 34.1%, respectively, over
the same quarter in 2013. International sales currently represent
10.5% of total sales.
Non-GAAP Adjusted EBITDA for the quarter was 35.4% of net sales,
compared to 34.0% for the second quarter last year. Non-GAAP net
income for the quarter, which excludes the provisions for
litigation, was $21.5 million, or $0.23 per diluted share, as
compared to $20.0 million, or $0.21 per diluted share, for 2013.
GAAP net income for the quarter was $20.6 million, or $0.22 per
diluted share, as compared to $7.4 million, or $0.08 per diluted
share, in the second quarter of 2013.
Cash, cash equivalents and marketable securities ended the
quarter at $313.0 million, increasing by $8.1 million during the
quarter. The company remains debt free.
Revenue and Non-GAAP Diluted Earnings per Share
Guidance
The company today revised its 2014 revenue guidance and now
expects full year net sales to be in the range of $460 to $465
million. Full year Non-GAAP diluted earnings per share guidance
remained unchanged, and is expected to be in the range of $0.90 to
$0.92 per share of common stock.
Conference Call Information
Globus Medical will hold a teleconference to discuss its 2014
first quarter results with the investment community at 5:30 p.m.
Eastern Time today. Globus invites all interested parties to join
the call by dialing:
1-855-533-7141 United States Participants 1-720-545-0060
International Participants There is no pass code for the
teleconference.
For interested parties who do not wish to ask questions, the
teleconference will be webcast live and may be accessed through a
link on the Globus Medical website at
investors.globusmedical.com.
If you are unable to participate during the live teleconference,
the call will be archived until Tuesday, August 19, 2014. The audio
archive can be accessed by calling 1-855-859-2056 in the U.S. or
1-404-537-3406 from outside the U.S. The pass code for the audio
replay is 2863-3213.
About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal implant
company based in Audubon, PA. The company was founded in 2003 by an
experienced team of professionals with a shared vision to create
products that enable surgeons to promote healing in patients with
musculoskeletal disorders.
Non-GAAP Financial Measures
To supplement our financial statements prepared in accordance
with U.S. generally accepted accounting principles (“U.S. GAAP”),
management uses certain non-GAAP financial measures. For example,
Adjusted EBITDA, which represents net income before interest
(income)/expense, net and other non-operating expenses, provision
for income taxes, depreciation and amortization, stock-based
compensation, changes in the fair value of acquisition-related
contingent consideration, provision for litigation and provision
for litigation - cost of goods sold, is useful as an additional
measure of operating performance, and particularly as a measure of
comparative operating performance from period to period, as it is
reflective of changes in pricing decisions, cost controls and other
factors that affect operating performance, and it removes the
effect of our capital structure, asset base, income taxes and
interest income and expense. Our management also uses Adjusted
EBITDA for planning purposes, including the preparation of our
annual operating budget and financial projections. In addition, for
the periods ended June 30, 2014 and for other comparative periods,
we are presenting non-GAAP net income and non-GAAP diluted earnings
per share, which represent net income and diluted earnings per
share, respectively, before provisions for litigation, which is net
of the tax effects of such provisions. We believe these non-GAAP
measures are also useful indicators of our operating performance,
and particularly as additional measures of comparative operative
performance from period to period as they remove the effects of
litigation, which we believe are not reflective of underlying
business trends. We also define the non-GAAP measure of Free Cash
Flow as the net cash provided by operating activities less the cash
impact of purchases of property and equipment. We believe that this
financial measure provides meaningful information for evaluating
our overall financial performance for comparative periods as it
facilitates an assessment of funds available to satisfy current and
future obligations and fund acquisitions.
Adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings
per share and Free Cash Flow are not calculated in conformity with
U.S. GAAP. Non-GAAP financial measures have limitations as
analytical tools and should not be considered in isolation or as a
substitute for financial measures prepared in accordance with U.S.
GAAP. These measures do not include certain expenses that may be
necessary to evaluate our liquidity or operating results. Our
definitions of Adjusted EBITDA, non-GAAP net income, non-GAAP
diluted earnings per share and Free Cash Flow may differ from that
of other companies and therefore may not be comparable.
Safe Harbor Statements
All statements included in this press release other than
statements of historical fact are forward-looking statements and
may be identified by their use of words such as “believe,” “may,”
“might,” “could,” “will,” “aim,” “estimate,” “continue,”
“anticipate,” “intend,” “expect,” “plan” and other similar terms.
These forward-looking statements are based on our current
assumptions, expectations and estimates of future events and
trends. Forward-looking statements are only predictions and are
subject to many risks, uncertainties and other factors that may
affect our businesses and operations and could cause actual results
to differ materially from those predicted. These risks and
uncertainties include, but are not limited to, factors affecting
our quarterly results, our ability to manage our growth, our
ability to sustain our profitability, demand for our products, our
ability to compete successfully (including without limitation our
ability to convince surgeons to use our products and our ability to
attract and retain sales and other personnel), our ability to
rapidly develop and introduce new products, our ability to develop
and execute on successful business strategies, our ability to
comply with laws and regulations that are or may become applicable
to our businesses, our ability to safeguard our intellectual
property, our success in defending legal proceedings brought
against us, trends in the medical device industry, general economic
conditions, and other risks. For a discussion of these and other
risks, uncertainties and other factors that could affect our
results, you should refer to the disclosure contained in our most
recent annual report on Form 10-K filed with the Securities and
Exchange Commission, including the sections labeled “Risk Factors”
and “Cautionary Note Concerning Forward-Looking Statements,” and in
our Forms 10-Q, Forms 8-K and other filings with the Securities and
Exchange Commission. These documents are available at www.sec.gov.
Moreover, we operate in an evolving environment. New risk factors
and uncertainties emerge from time to time and it is not possible
for us to predict all risk factors and uncertainties, nor can we
assess the impact of all factors on our business or the extent to
which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any
forward-looking statements. Given these risks and uncertainties,
readers are cautioned not to place undue reliance on any
forward-looking statements. Forward-looking statements contained in
this press release speak only as of the date of this press release.
We undertake no obligation to update any forward-looking statements
as a result of new information, events or circumstances or other
factors arising or coming to our attention after the date
hereof.
GLOBUS MEDICAL, INC. AND
SUBSIDIARIES
CONSOLIDATED STATEMENTS OF
INCOME
(unaudited)
Three Months Ended Six Months
Ended June 30, June 30, June 30,
June 30,
(In thousands, except per share
amounts)
2014 2013 2014 2013 Sales
$ 113,573 $ 107,009
$ 227,783 $ 212,027
Cost of goods sold
26,583 23,501
51,895 46,994
Provision for litigation - cost of goods sold
0
1,260
0 1,260
Gross
profit 86,990 82,248
175,888 163,773 Operating expenses: Research
and development
7,694 7,037
15,137 13,884 Selling,
general and administrative
46,425 45,750
93,103
91,147 Provision for litigation
1,318 18,269
3,853 18,319
Total operating
expenses 55,437 71,056
112,093 123,350
Operating income
31,553 11,192
63,795 40,423 Other income/(expense),
net
325 (221 )
570 58
Income before income taxes 31,878 10,971
64,365 40,481 Income tax provision
11,231
3,545
22,579 13,164
Net income $ 20,647 $ 7,426
$
41,786 $ 27,317
Earnings per share: Basic
$ 0.22 $ 0.08
$ 0.44 $ 0.30
Diluted
$ 0.22 $ 0.08
$ 0.44 $
0.29
Weighted average shares outstanding: Basic
94,212 92,415
93,965
92,110 Diluted
95,480 93,970
95,328 93,772
GLOBUS MEDICAL, INC. AND
SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except par value) June 30, 2014
December 31, 2013 (unaudited) ASSETS
Current assets: Cash and cash equivalents
$
136,500 $ 89,962 Short-term marketable securities
139,765 148,962 Accounts receivable, net of allowances of
$1,554 and $1,581, respectively
65,054 62,414 Inventories
76,362 70,350 Prepaid expenses and other current assets
5,412 5,080 Income taxes receivable
4,690 2,723
Deferred income taxes
39,317 37,317
Total current assets 467,100
416,808 Property and equipment, net of accumulated
depreciation of $109,342 and $99,910, respectively
65,572
64,150 Long-term marketable securities
36,754 36,528
Intangible assets, net
29,271 29,537 Goodwill
18,372
18,372 Other assets
931 909
Total assets $ 618,000 $ 566,304
LIABILITIES AND EQUITY Current liabilities:
Accounts payable
8,814 10,073 Accounts payable to related
party
4,159 2,656 Accrued expenses
51,366 51,125
Income taxes payable
212 2,358 Business acquisition
liabilities, current
1,419 1,730
Total current liabilities 65,970
67,942 Business acquisition liabilities, net of current
portion
15,449 15,528 Deferred income taxes
4,147
6,385 Other liabilities
4,124 4,089
Total liabilities 89,690
93,944
Commitments and contingencies Equity:
Common stock; $0.001 par value. Authorized 785,000 shares; issued
and outstanding 94,367 and 93,443 shares at June 30, 2014 and
December 31, 2013, respectively
94 93 Additional paid-in
capital
168,008 153,987 Accumulated other comprehensive loss
(867 ) (1,009 ) Retained earnings
361,075 319,289
Total equity
528,310 472,360
Total
liabilities and equity $ 618,000 $ 566,304
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
Six Months Ended (In thousands) June
30, 2014 June 30, 2013 Cash
flows from operating activities: Net income
$
41,786 $ 27,317 Adjustments to reconcile net income to net
cash provided by operating activities: Depreciation and
amortization
10,684 9,352 Amortization of premium on
marketable securities
1,566 755 Provision for excess and
obsolete inventories
3,535 3,463 Stock-based compensation
3,550 2,478 Allowance for doubtful accounts
112 89
Change in deferred income taxes
(4,231 ) (5,806 )
(Increase)/decrease in: Accounts receivable
(2,491 )
(4,410 ) Inventories
(9,494 ) (12,955 ) Prepaid
expenses and other assets
(384 ) (2,501 )
Increase/(decrease) in: Accounts payable
(821 ) 243
Accounts payable to related party
1,503 2,645 Accrued
expenses and other liabilities
385 15,824 Income taxes
payable/receivable
(4,118 ) (9,238 )
Net cash
provided by operating activities 41,582 27,256
Cash flows from investing activities:
Purchases of marketable securities
(105,015 )
(144,062 ) Maturities of marketable securities
95,292 3,900
Sales of marketable securities
17,155 — Purchases of
property and equipment
(12,231 ) (12,956 )
Net
cash used in investing activities (4,799 )
(153,118 )
Cash flows from financing activities:
Payment of business acquisition liabilities
(600 )
(700 ) Proceeds from issuance of common stock
6,631 4,254
Excess tax benefit related to nonqualified stock options
3,841 2,187
Net cash provided by financing
activities 9,872 5,741 Effect of
foreign exchange rate on cash
(117 ) 35
Net increase/(decrease) in cash and cash equivalents
46,538 (120,086 ) Cash and cash equivalents, beginning of
period
89,962 212,400
Cash and cash
equivalents, end of period $ 136,500 $
92,314 Supplemental disclosures of cash flow
information: Interest paid
25 30 Income taxes paid
$
27,122 $ 25,891 The following tables
reconcile GAAP to Non-GAAP financial measures. Non-GAAP
Adjusted EBITDA Reconciliation Table:
(Unaudited)
Three Months Ended Six Months Ended (In thousands,
except percentages) June 30, 2014 June
30, 2013 June 30, 2014 June
30, 2013 Net income
$ 20,647 $ 7,426
$ 41,786 $ 27,317 Interest income, net
(195
) (144 )
(396 ) (190 ) Provision for income
taxes
11,231 3,545
22,579 13,164 Depreciation and
amortization
5,387 4,742
10,684
9,352 EBITDA
37,070 15,569
74,653 49,643
Stock-based compensation
1,623 1,166
3,550 2,478
Provision for litigation
1,318 18,269
3,853 18,319
Provision for litigation - cost of goods sold
— 1,260
— 1,260 Change in fair value of acquisition-related
contingent consideration
143 74
153
144 Adjusted EBITDA
$ 40,154 $
36,338
$ 82,209 $ 71,844
Adjusted EBITDA as a percentage of sales
35.4 % 34.0
%
36.1 % 33.9 %
Non-GAAP Net Income Reconciliation
Table:
(Unaudited) Three Months Ended Six Months
Ended (In thousands) June 30, 2014
June 30, 2013 June 30, 2014
June 30, 2013 Net income
$ 20,647 $
7,426
$ 41,786 $ 27,317 Provision for litigation, net
of taxes
854 11,802
2,497 11,834 Provision for
litigation - cost of goods sold, net of taxes
— 814
— 814 Non-GAAP Net Income
$
21,501 $ 20,042
$ 44,283
$ 39,965
Non-GAAP Diluted Earnings Per Share
Reconciliation Table:
(Unaudited) Three Months Ended Six Months
Ended (Per share amounts) June 30, 2014
June 30, 2013 June 30, 2014
June 30, 2013 Diluted earnings per share, as
reported
$ 0.22 $ 0.08
$ 0.44 $ 0.29
Provision for litigation, net of taxes
0.01 0.12
0.02
0.13 Provision for litigation - cost of goods sold, net of taxes
— 0.01
— 0.01 Non-GAAP
diluted earnings per share
$ 0.23 $ 0.21
$ 0.46 $ 0.43
Non-GAAP Free Cash Flow Reconciliation
Table:
(Unaudited) Three Months Ended Six Months
Ended (In thousands) June 30, 2014
June 30, 2013 June 30, 2014
June 30, 2013 Net cash provided by operating
activities
$ 12,350 $ 8,980
$ 41,582 $
27,256 Purchases of property and equipment
(6,067 )
(6,184 )
(12,231 ) (12,956 ) Non-GAAP free cash flow
$ 6,283 $ 2,796
$ 29,351
$ 14,300
The following table highlights certain
information related to our liquidity and capital resources:
(In thousands) June 30, 2014
December 31, 2013 (unaudited) Cash and
cash equivalents
$ 136,500 $ 89,962 Short-term
marketable securities
139,765 148,962 Long-term marketable
securities
36,754 36,528 Total cash, cash
equivalents and marketable securities
$ 313,019
$ 275,452 Available borrowing capacity under
revolving credit facility
50,000 50,000 Working capital
$ 401,130 $ 348,866
Globus Medical, Inc.Ed JoyceDirector, Investor
Relations610-930-1800investors@globusmedical.comwww.globusmedical.com
Globus Medical (NYSE:GMED)
Historical Stock Chart
From Mar 2024 to Apr 2024
Globus Medical (NYSE:GMED)
Historical Stock Chart
From Apr 2023 to Apr 2024